Yüklüyor......

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis

Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment model. Only weight was included in the final model, as o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Pharmacol
Asıl Yazarlar: Bruin, Gerard, Loesche, Christian, Nyirady, Judit, Sander, Oliver
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5485066/
https://ncbi.nlm.nih.gov/pubmed/28273356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.876
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!